32 results · 19ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

Abbott Rapid Diagnostics Jena GmbH

Manufacturer
🇩🇪 Germany

ABBOTT GmbH

FDA registration
ABBOTT GmbH·137 products·🇩🇪 Germany

Abbott Automation Solutions GmbH

FDA registration
Abbott Automation Solutions GmbH·6 products·🇩🇪 Germany

Abbott Diagnostics GmbH

Importer
🇩🇪 Germany·6 Manufacturers

Abbott GmbH

Authorized representative
🇩🇪 Germany·4 Manufacturers

Alinity c Carbon Dioxide Reagent Kit, Produced for Abbott by Sekisui Diagnostics P.E.I. Inc. Prince Edward Island Canada

FDA Enforcement
Class II ·Terminated·Abbott GmBH & Co. KG·December 4, 2019

Abbott GmbH

Importer
🇩🇪 Germany·3 Manufacturers

LN 3R70-01; software version 2.6.2 and earlier. The software is used with the Alinity i (LN 03R65-01) processing module and the Alinity c (LN 03R67-01) processing module.

FDA Enforcement
Class II ·Terminated·Abbott Gmbh & Co. KG·April 1, 2020

ARCHITECT HAVAB-G Calibrator, REF 6L27-01

FDA Enforcement
Class II ·Terminated·Abbott Gmbh & Co. KG·December 4, 2019

ARCHITECT iGentamicin Reagent Kit - Product Usage: The measurements obtained are used in the diagnosis and treatment of gentamicin overdose and in monitoring levels of gentamicin to help ensure appropriate therapy.

FDA Enforcement
Class II ·Ongoing·Abbott Gmbh & Co. KG·June 3, 2020

Alinity i Processing Module, (a) Part Number 03R65-01 (b) Part Number A-30108552-01 (c) Part Number A-30109694-01 Product Usage: The Alinity i processing module is a fully automated immunoassay analyzer allowing random and continuous access, as well as priority and automated retest processing using chemiluminescent microparticle immunoassay (CMIA) technology. CMIA technology is used to determine the presence of antigens, antibodies, and analytes in samples.

FDA Enforcement
Class II ·Terminated·Abbott Gmbh & Co. KG·February 6, 2019

Alinity ci -series System Control¿Module, Part Number 03R70 01 Product Usage: The Alinity ci series System Control Module has a scalable design to provide full integration of clinical chemistry and immunoassay analysis. The Alinity ci series System Control Module includes a clinical chemistry module and an immunoassay module, each performing all sample processing activities, and a system control module to provide a single user friendly interface. Each system can be customized by combining one or more sample processing modules, in multiple configurations, with a system control module to form a single workstation. The Alinity i Processing Module is a fully automated immunoassay analyzer allowing random and continuous access, as well as priority and automated retest processing using chemiluminescent microparticle immunoassay (CMIA) technology. CMIA technology is used to determine the presence of antigens, antibodies, and analytes in samples.

FDA Enforcement
Class II ·Terminated·Abbott Gmbh & Co. KG·September 4, 2019

Abbott Diagnostics GmbH

Authorized representative
🇩🇪 Germany

IBP cable Becton Dickinson (2606488); IBP cable Edwards (2606489); IBP cable Abbott, Medex (2606490); IBP cable Utah (2606491); IBP Adapter Cable Draeger 7pin (2607558); IBP Adapter Cable Draeger 10pin (2607559)

FDA 510(k)
FDA Class 2 ·Cardiovascular

Abbott Alinity ci-series System Control Module software version 2.5.1; LN 3R70-01 with the following hardware: Level Sensor, Bulk Solution; 04S68-01, Accessory Kit, Alinity I; 03R66-01and 03R66-02 , and Accessory Kit, Alinity c; 03R69-01 and 03R69-02. Product Usage: The Alinity i (LN 03R65 01) processing module is a fully automated immunoassay analyzer allowing random and continuous access, as well as priority and automated retest processing using chemiluminescent microparticle immunoassay (CMIA) technology. CMIA technology is used to determine the presence of antigens, antibodies, and analytes in samples. The Alinity c (LN 03R67 01) processing module is a fully automated chemistry analyzer allowing random and continuous access, as well as priority and automated retest processing using photometric and potentiometric detection technology. The Alinity c processing module uses photometric detection technology to measure sample absorbance for the quantification of analyte concentration and uses potentiometric detection technology to measure the electrical potential in a sample. In addition, the Alinity c processing module uses an integrated chip technology (ICT) module to measure potentiometric assays (electrolytes).

FDA Enforcement
Class II ·Terminated·Abbott Gmbh & Co. KG·May 22, 2019

Abbott Alinity i Processing Module LN 03R65-01 - Product Usage: The Alinity i processing module is a fully automated immunoassay analyzer allowing random and continuous access, as well as priority and automated retest processing using chemiluminescent microparticle immunoassay (CMIA) technology. CMIA technology is used to determine the presence of antigens, antibodies, and analytes in samples.

FDA Enforcement
Class II ·Terminated·Abbott Gmbh & Co. KG·April 24, 2019

ARCHITECT Anti-HCV Reagent Kit, List Numbers: a) 1L79-25, b) 1L79-35

FDA Enforcement
Class II ·Ongoing·Abbott GmbH·April 10, 2024

Alinity i Anti-HCV Reagent Kit, List Number 08P0521

FDA Enforcement
Class II ·Ongoing·Abbott GmbH·April 10, 2024

Abbott Rapid Diagnostics Jena GmbH

System producer
🇩🇪 Germany

Abbott Alinity c Processing Module LN 03R67-01 - Product Usage: The Alinity c processing module is a fully automated chemistry analyzer allowing random and continuous access, as well as priority and automated retest processing using photometric and potentiometric detection technology. The Alinity c processing module uses photometric detection technology to measure sample absorbance for the quantification of analyte concentration and uses potentiometric detection technology to measure the electrical potential in a sample. In addition, the Alinity c processing module uses an integrated chip technology (ICT) module to measure potentiometric assays (electrolytes).

FDA Enforcement
Class II ·Terminated·Abbott Gmbh & Co. KG·April 24, 2019